Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-M201 in mild-to-moderately active ulcerative colitis
NCT03923478Phase 1Terminated
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Jun 2019
- Primary completion
- Jan 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ABI-M201 in ulcerative colitis (UC) (4 cohorts), sponsored by Assembly Biosciences, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 8 weeks and Incidence of Treatment-Emergent Laboratory Abnormalities at 8 weeks. Started Jun 2019; status: terminated.
02
Drugs
ABI-M201
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03923478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923478.